1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
- 2019
-
Mark
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
(
- Contribution to journal › Article
- 2017
-
Mark
Chronic lymphocytic leukemia with mutated IGHV4-34 receptors : Shared and distinct immunogenetic features and clinical outcomes
(
- Contribution to journal › Article
- 2016
-
Mark
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
(
- Contribution to journal › Article
- 2015
-
Mark
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Scientific review
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
- 2010
-
Mark
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma First Results from an International Phase II Clinical Trial
(
- Contribution to journal › Published meeting abstract